×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2018
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Sarcoma

Gina Columbus
CURE spoke with Noah Federman about the prevalence and treatment of sarcomas in younger patients. 
Jason M. Broderick
The FDA granted olaratumab a priority review for some people with advanced soft tissue sarcoma (STS). 
Rebekah Harrison
When it comes to fighting sarcoma, the Sarcoma Foundation of America does not stop at fundraising.
Jason M. Broderick
The breakthrough designation will expedite the development and review of this novel T-cell therapy in synovial sarcoma.
Silas Inman
The approval of Halaven was based on an improvement in overall survival (OS) in a phase 3 study.
Andrew J. Roth
Based on this study, the monoclonal antibody is being investigated in an ongoing phase 3 study and has received an FDA Breakthrough Therapy Designation.
Jason M. Broderick
The approval is based on results from the phase 3 ET743-SAR-3007 trial.
Letitia L. Star
Caregivers may grapple with practical and emotional challenges as they help loved ones manage cancer-related pain.
Silas Inman
Treatment with eribulin mesylate significantly extended overall survival (OS) compared with dacarbazine in patients with advanced soft tissue sarcoma, according to topline results from a phase 3 clinical trial.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

In Treatment

Maintenance/Hormone Treatment

Out of Treatment

Caregiver

Healthcare Professional

Not Applicable